^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TROP-2 inhibitor

    Related drugs:
    Associations

    News

    Trials
    12d
    A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov)
    P1/2, N=428, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • Padcev (enfortumab vedotin-ejfv)
    1m
    MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. (PubMed, Future Oncol)
    Here, we present the protocol design for study MDX-2001-101, a multicenter, open-label, phase I/IIa clinical trial designed to evaluate the safety, tolerability, and antitumor effects of MDX2001 in patients with advanced solid tumors. The study comprises a phase Ia dose escalation guided by a Bayesian optimal interval design with a targeted maximum tolerated dose toxicity rate of 30%, a phase Ib dose expansion, and a phase IIa indication expansion.
    P1/2 data • Journal • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    2ms
    A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov)
    P1/2, N=428, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • Padcev (enfortumab vedotin-ejfv)
    8ms
    A Clinical Trial With KJ103 in Anti-GBM Disease (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Shanghai Bao Pharmaceuticals Co., Ltd. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide
    8ms
    Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=51, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2028 --> Jan 2028 | Trial primary completion date: Jul 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK
    1year
    Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (clinicaltrials.gov)
    P1, N=42, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
    over1year
    A Clinical Trial with KJ103 in Anti-GBM Disease (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, Shanghai Bao Pharmaceuticals Co., Ltd.
    New P2 trial
    |
    cyclophosphamide
    over1year
    A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults (clinicaltrials.gov)
    P1, N=34, Completed, Shanghai Bao Pharmaceuticals Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Apr 2023 --> Aug 2023
    Trial completion • Trial completion date
    over1year
    Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jan 2027 --> Jan 2029
    Trial primary completion date • Combination therapy • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
    almost2years
    Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Combination therapy • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
    2years
    Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) (clinicaltrials.gov)
    P1, N=54, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2028 --> Apr 2038
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
    2years
    Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=51, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    BRCA2 mutation • BRCA1 mutation • TROP2 expression
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK